

## Two New Monoterpenes from *Tithonia diversifolia* and Their Anti-Hyperglycemic Activity

Xia Li<sup>1</sup>, Guanghui Huang<sup>1,2</sup>, Guijun Zhao<sup>1</sup>, Wansheng Chen<sup>3</sup>, Junli Li<sup>1,2</sup>  
and Lianna Sun<sup>1\*</sup>

<sup>1</sup>School of Pharmacy, Second Military Medical University, Guohe Road 325#, Shanghai 200433, P.R China;

<sup>2</sup>Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, Fujian, PR China

<sup>3</sup>Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Fengyang Road 415#, Shanghai 200003, P.R China

(Received January 10, 2013; Revised June 21, 2013; Accepted July 12, 2013)

**Abstract:** Two new monoterpenes: ((1*S*,2*R*,3*R*,5*S*)-2-hydroxymethyl-6,6-dimethylbicyclo[3.1.1]heptane-2,3-diol (**1**) and (3*R*)-6,6-dimethyl-4-methylenebicyclo[3.1.1]heptane-1,3-diol-3-*O*- $\beta$ -D-glucopyranoside (**2**), along with three known compounds, namely, sobrerol (**3**), (1*R*,2*S*,5*S*)-2,8-*p*-menth-diol (**4**) and (1*R*,5*S*)-10-hydroxyverbenon (**5**), were isolated from aerial part of *Tithonia diversifolia*. Their structures were determined on the basis of spectroscopic analyses (IR, HR-ESI-MS/MS, 1D/2D NMR). Under the concentration of 10  $\mu$ g/mL, compounds **1** and **3** significantly increased glucose uptake in 3T3-L1 adipocytes without significant toxic effects *in vitro*.

**Keywords:** *Tithonia diversifolia*; Monoterpene; 3T3-L1 adipocytes; Anti-hyperglycemic activity.

### 1. Plant Source

*Tithonia diversifolia* (Hemsl.) A. Gray (Asteraceae: Heliantheae), known as Mexican sunflower, is a native plant of Mexico and Central America [1]. As our continuing research on antidiabetic active metabolites from *T. diversifolia*, we report the isolation and identification of two new monoterpenes and three known monoterpenes. Furthermore, the anti-hyperglycemic activities of compounds **1–5** were evaluated for glucose uptake in 3T3-L1 adipocytes.

The aerial parts of *T. diversifolia* (Hemsl.) A. Gray were collected in Mengzi of Yunnan province, China in September 2007 and identified by Prof. Wansheng Chen (Department of Pharmacy, Changzheng Hospital, Second Military Medical University). A voucher specimen (NO.TD20070927) was deposited in the Department of Pharmacognosy of Second Military Medical University in Shanghai, P.R China.

### 2. Previous Studies

*T. diversifolia* is used traditionally for the treatment of malaria, fever or wound in Mexico. Modern pharmacological investigations revealed that it has extensive bioactivities including antimalarial [2], antidiabetic [3], anti-inflammatory [4], and anticancer [5]. Phytochemical studies on this species have resulted in the isolation of sesquiterpene lactones, chromenes, and flavones [6-8].

\*Corresponding author. E-mail: [sssnmr@163.com](mailto:sssnmr@163.com); Phone: 086-21-81871308 Fax: 086-21-81871308


### 3. Present Study

The dried aerial parts (21 kg) of *Tithonia diversifolia* were percolated with 80% EtOH at room temperature. The EtOH extract was concentrated to an aqueous residue (2.48 kg) and suspended with water. The water layer was extracted with petroleum ether, EtOAc and n-BuOH. The EtOAc fraction (128.0 g) was separated by column chromatography using silica gel as a packing agent and petroleum ether-EtOAc as a solvent mixture, which resulted in six major fractions (1-6). Fraction 2 (6.5 g) was further separated by chromatography using Sephadex LH-20 and silica gel to obtain compound **3** (49.1 mg) [9]. Fraction 3 (28.6 g) was subject to MCI gel column chromatography, eluting with a mixture of MeOH-H<sub>2</sub>O, which gave six parts (3.1-3.6). Fraction 3.1(4.6 g) was separated by a silica gel column chromatography to obtain five parts (3.1.1-3.1.5). The subfractions 3.1.3(0.6 g) and 3.1.2(1.0 g) were further separated by using preparative TLC to yield compounds **1** (9.8 mg) and **4** (12.6 mg) [9]. Fraction 3.1.5 (2.1 g) was further fractionated using Sephadex LH-20, which gave five parts (3.1.5.1-3.1.5.5), and Fraction 3.1.5.5 (0.6 g) was purified by a silica gel column chromatography to obtain compound **5** (28.1 mg) [10]. Fraction 6 (23.7 g) was subject to MCI gel column chromatography to yield four parts (6.1-6.4). Then, the subfraction 6.1(3.5 g) was subjected to ODS silica gel column chromatography to give compound **2** (38.2 mg).


(+)-2-hydroxymethyl-6,6-dimethylbicyclo[3.1.1]heptane-2 $\alpha$ ,3 $\alpha$ -diol (**1**): Colorless raphide;  $[\alpha]_D^{20} = +18^\circ$  (c=0.14, acetone); IR (KBr): 3420, 3348, 3001, 2978, 2953, 2923, 2868, 1644, 1577, 1419, 1384, 1174, 1029, 1002, 971, 886, 863, 758 cm<sup>-1</sup>; <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  1.82(dd, J=5.4 and 6.0 Hz, H-1), 4.31(dd, J=2.4, 9.0 Hz, H-3), 2.60(ddt, J=2.4, 9.0, 13.8 Hz, H-4a), 1.68(dt, J=3.0, 13.8 Hz, H-4b), 1.95(ddt, J=2.4, 3.0, 5.4 Hz, H-5), 2.24(ddt, J=2.4, 6.0, 13.2 Hz, H-7a), 1.24(d, J=13.2 Hz, H-7b), 1.25(s, H-8), 1.04(s, H-9), 4.16(d, F=10.8 Hz, H-10a), 3.26(d, J=10.8 Hz, H-10b). <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  49.7(C-1), 80.2(C-2), 74.4(C-3), 37.2(C-4), 40.6(C-5), 38.7(C-6), 26.9(C-7), 27.1(C-8), 23.7(C-9), 68.3(C-10). HR-ESI-MS: *m/z* 209.1119 [M+Na]<sup>+</sup> (calcd for C<sub>10</sub>H<sub>18</sub>NaO<sub>3</sub>, 209.1148).

(-)-6,6-dimethyl-4-methylenebicyclo[3.1.1]heptane-1 $\alpha$ ,3 $\alpha$ -diol-3-O- $\beta$ -D-glucopyranoside (**2**):  $[\alpha]_D^{20} = -44.1^\circ$  (c=0.24, MeOH); <sup>1</sup>H-NMR (600 MHz, pyridine-*d*<sub>5</sub>):  $\delta$  2.81(d, J=12.0 Hz, H-2a), 2.43(dd, J=7.8, 12.0 Hz, H-2b), 4.88(dd, J=7.2 Hz, H-3), 2.36(d, J=6.6 Hz, H-5), 2.48(d, J=15.2 Hz, H-7a), 2.48(dd, J=6.6, 15.2 Hz, H-7b), 0.74(s, H-8), 1.35(s, H-9), 5.25(s, H-10a), 5.04(s, H-10b), 5.12(d, J=7.8 Hz, H-1'), 4.05(dd, J=7.8, 8.4 Hz, H-2'), 4.21(dd, J=8.4, 9.6 Hz, H-3'), 4.18(d, J=9.6 Hz, H-4'), 3.89(d, J=6.6 Hz, H-5'), 4.54(d, J=11.4 Hz, H-6'a), 4.34(dd, J=6.0, 11.4 Hz, H-6'b). <sup>13</sup>C-NMR (150 MHz, pyridine-*d*<sub>5</sub>):  $\delta$  73.9(C-1), 35.3(C-2), 72.9(C-3), 146.7(C-4), 45.1(C-5), 47.6(C-6), 40.5(C-7), 20.0(C-8), 21.9(C-9), 114.8(C-10), 99.1(C-1'), 74.9(C-2'), 78.6(C-3'), 71.7(C-4'), 78.1(C-5'), 62.7(C-6'). HR-ESI-MS: *m/z* 375.1669 [M+COOH]<sup>+</sup>, 353.1575 [M+Na]<sup>+</sup>.

**Bioactivity Test- Agar diffusion test:** The differentiated 3T3-L1 adipocytes, plated into 96-well plates were pre-incubated with DMEM, containing 0.2% BSA, and then incubated with various concentrations of the compounds **1-5** (10  $\mu$ g/mL) for 12 hours. The amounts of glucose uptake were calculated by the glucose concentrations of blank wells, subtracting the remaining glucose in the cell-plated wells. Meanwhile, MTT assay was performed to monitor the cell proliferation and adjust the glucose uptake values.



**Figure 1.** <sup>1</sup>H-<sup>1</sup>H COSY correlations and the key HMBC correlations of compound **1-2**



**Figure 2.** Key ROESY correlations of compound **1** and **2**

Compound **1** was obtained as a needle crystal. The HR-ESI-MS ( $m/z$  219.1119  $[M+Na]^+$ ) and NMR data (Table 1) explained the molecular formula of compound **1** as  $C_{10}H_{18}O_3$ , indicating two degrees of unsaturation. The structure of the compound was established through detailed analyses of its  $^1H$  and  $^{13}C$  NMR spectra, including 2D NMR. The  $^{13}C$  NMR spectrum of **1** exhibited 10 signals, together with the information from a DEPT spectrum, corresponding to two methyl, three methylenes, three methines, and two quaternary carbons. One oxygenated methane ( $\delta_C$  74.4), one oxygenated methylene ( $\delta_C$  68.3) and one oxygenated quaternary carbon ( $\delta_C$  80.2) were among the signals. The  $^1H$ -NMR spectrum of compound **1** displayed two methyls at  $\delta_H$  1.04 (s,  $CH_3$ -9) and  $\delta_H$  1.25 (s,  $CH_3$ -8), assigned to  $\delta_C$  23.7 (C-9) and  $\delta_C$  27.1 (C-8), respectively, according to the HSQC correlations; an oxygenated methylene group at  $\delta_H$  4.16 (d,  $J=10.8$  Hz, H-10a) and  $\delta_H$  3.26 (d,  $J=10.8$  Hz, H-10b), showing correlation with  $\delta_C$  68.3 (C-10) in the HSQC and one oxygenated methane at  $\delta_H$  4.31 (dd,  $J=2.4, 9.0$  Hz, H-3), assigned to  $\delta_C$  74.4 (C-3), which were further confirmed by the HSQC correlations. The  $^1H$ - and  $^{13}C$ -NMR spectroscopic data (Table 1) as well as the observed HSQC and HMBC correlations (Fig 1) suggested that compound **1** is a pinane monoterpene. The methine signal at  $\delta_C$  49.7 (C-1) was attached at  $\delta_C$  26.9 (C-7) due to the  $^1H$ - $^1H$  COSY correlation of  $\delta_H$  1.82 (H-1) to  $\delta_H$  2.24 (H-7). Similarly,  $\delta_C$  26.9 (C-7) attached to  $\delta_C$  40.6 (C-5);  $\delta_C$  40.6 (C-5) attached to  $\delta_C$  37.2 (C-4) and  $\delta_C$  37.2 (C-4) attached to  $\delta_C$  74.4 (C-3) were further confirmed by the  $^1H$ - $^1H$  COSY correlations (H-7/H-5, H-5/H-4 and H-4/H-3). The oxygenated quaternary carbon at  $\delta_C$  80.2 was assigned to C-2, which showed correlations with H-1 ( $\delta_H$  1.82), H-3 ( $\delta_H$  4.31) and H-7 ( $\delta_H$  2.24) by the HMBC measurements. The remaining quaternary carbon at  $\delta_C$  38.7 was assigned to C-6, which showed correlations with H-1 ( $\delta_H$  1.82) and H-4 ( $\delta_H$  1.68) in the HMBC. The oxygenated methylene ( $\delta_C$  68.3) was attached to C-2 ( $\delta_C$  80.2), confirming by the HMBC correlations from H-10b ( $\delta_H$  3.26) to C-1 ( $\delta_C$  49.7), C-2 ( $\delta_C$  80.2) and C-3 ( $\delta_C$  68.3). The two methyl C-8 ( $\delta_C$  27.1) and C-9 ( $\delta_C$  23.7) were located at the C-6, which was identified by the HMBC correlations from H-8 ( $\delta_H$  1.25) and H-9 ( $\delta_H$  1.04) to C-1 ( $\delta_C$  49.7), C-6 ( $\delta_C$  38.7) and C-5 ( $\delta_C$  40.6). The  $\alpha$ -orientation of the hydroxyl groups at C-2 and C-3 were established by the ROESY correlations of the H-8/H-10a and H-3/H-8. Furthermore, the ROESY correlations of H-1/H-5, H-1/H-10 indicated that the H-1 and H-5 had  $\alpha$ -orientations, then the configuration of compound **1** could be established as shown in Fig 1. Thus, based on the above evidences, compound **1** was assigned as (+)-2-hydroxymethyl-6,6-dimethylbicyclo[3.1.1]heptane-2 $\alpha$ ,3 $\alpha$ -diol. Compound **2** was obtained as a colorless oil. The positive-ion HR-ESI-MS showed a quasimolecular ion at  $m/z$  353.1572  $[M+Na]^+$ , and negative-ion HR-ESI-MS at  $m/z$  375.1669  $[M+COOH]^-$  corresponding to a molecular formula of  $C_{16}H_{26}O_7$ , requiring four degrees of unsaturation. The  $^1H$ -NMR spectrum of compound **2** displayed two methyl groups at  $\delta_H$  1.35 (s) and  $\delta_H$  0.74 (s), respectively, two olefinic protons as broad singlets at  $\delta_H$  5.04 (br, s) and 5.25 (br, s) and an oxygenated methine at  $\delta_H$  4.88 ( $J=7.2$  Hz). The  $^{13}C$ -NMR spectrum exhibited five oxygenated methine carbons at  $\delta_C$  99.1, 74.9, 78.6, 71.7 and 78.1, and one methylene carbon at  $\delta_C$  62.7, indicating the presence of a glucose moiety, which was identified by GC analysis as D-glucose. Other carbon signals were identified by a DEPT experiment as two methyl, three methylene, three methane and two quaternary carbons, including one oxygenated methine group at  $\delta_C$  72.9 and one oxygenated carbonyl carbon at  $\delta_C$  73.9. The above assignments were characteristic for a glucopyranosyl moiety attached to  $\beta$ -pinene aglycone. The oxygenated carbonyl methine signal at  $\delta_C$  72.9 was assigned to C-3 due to the HMBC correlations with H-10 ( $\delta_H$  5.25 and 5.04), H-5 ( $\delta_H$  2.36) and H-2 ( $\delta_H$  2.43). The glucose moiety was located at the C-3, which was confirmed by the HMBC correlations of H-1' ( $\delta_H$  5.12) to C-3. The  $\beta$ -anomeric configuration for the glucose was determined by a large coupling constant of H-1' ( $\delta_H$  5.12, d,  $J=7.8$  Hz). The oxygenated carbonyl carbon signal at  $\delta_C$  73.9 was assigned to C-1 due to

the HMBC correlations of H-2 ( $\delta_{\text{H}}$  2.81 and 2.43), H-3 ( $\delta_{\text{H}}$  4.88), H-5 ( $\delta_{\text{H}}$  2.36), H-7 ( $\delta_{\text{H}}$  2.48), H-9 ( $\delta_{\text{H}}$  1.35) and H-8 ( $\delta_{\text{H}}$  0.74) to the carbonyl carbon. The remaining carbons and protons were confirmed at their respective positions based on analyses of the  $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$ , HMBC and HSQC dates. Structure of compound **2** was confirmed by a ROESY experiment (Fig 2). The hydroxyl groups at C-1 and C-3 were assigned as  $\alpha$ -orientations by the ROESY correlations of H7a/H3 and H10/H3. The  $\alpha$ -orientation of the H-5 was confirmed by the ROESY correlations of H7a/H3, H7b/H9 and H8/H2. Then, compound **2** was assigned as (-)-6,6-dimethyl-4-Methylenebicyclo[3.1.1]heptane-1 $\alpha$ ,3 $\alpha$ -diol-3-O- $\beta$ -D-glucopyranoside. Compounds **1–5** were evaluated for their anti-hyperglycemic activity based on glucose uptake in differentiated 3T3-L1 adipocytes. 10  $\mu\text{g/mL}$  of compounds **1** and **3** significantly increased glucose uptakes of 3T3-L1 adipocytes by 1.2- and 1.6- fold compared with the basal level, respectively. Cell viability was assayed by the MTT method, which indicated that the five compounds were not cytotoxic to fully differentiated 3T3-L1 adipocytes at this concentration.

## References

- [1] D. A. Chagas-Paula, R. B. Oliveira, V. C. Silva, L. Gobbo-Neto, T. H. Gasparoto, A. P. Campanelli, L. H. Faccioli and F. B. Da Costa (2011). Chlorogenic acids from *Tithonia diversifolia* demonstrate better anti-inflammatory effect than indomethacin and its sesquiterpene lactones, *J. Ethnopharmacol.* **136**, 355-362.
- [2] E. Goffin, E. Ziemo, P. D. Mol, M. D. C. D. Madureira, A. P. Martins, A. P. D. Cunha, G. Philippe, M. Tits, L. Angenot and M. Frederich (2002). In Vitro Antiplasmodial Activity of *Tithonia diversifolia* and Identification of its Main Active Constituent: Tagitinin C, *Planta Med.* **68**, 543-545.
- [3] T. Miura, K. Nosaka, H. Ishii and T. Ishida (2005). Antidiabetic effect of *Nitobegiku*, the herb *Tithonia diversifolia*, in KK-Ay diabetic mice, *Biol. Pharm. Bull.* **28**, 2152-2154.
- [4] V. B. Owoyele, C. O. Wuraola, A. O. Soladoye and S. B. Olaleye (2004). Studies on the anti-inflammatory and analgesic properties of *Tithonia diversifolia* leaf extract, *J. Ethnopharmacol.* **90**, 317-321.
- [5] J. Q. Gu, J. J. Gills, E. J. Park, E. Mata-Greenwood, M. E. Hawthorne, F. Axelrod, P. I. Chavez, H. H. S. Fong, R. G. Mehta, J. M. Pezzuto and A. D. Kinghorn (2002). Sesquiterpenoids from *Tithonia diversifolia* with potential cancer chemopreventive activity, *J. Nat. Prod.* **65**, 532-536.
- [6] S. R. Ambrosio, Y. Oki, V. C. G. Heleno, J. S. Chaves, P. G. B. D. Nascimento, J. E. Lichston, M. G. Constantino, E. M. Varanda and F. B. Da Costa (2008). Constituents of glandular trichomes of *Tithonia diversifolia*: relationships to herbivory and antifeedant activity, *Phytochemistry.* **69**, 2052-2060.
- [7] A. Schuster, S. Stokes, F. Papastergiou, V. Castro, L. Poveda and J. Jakupovic (1992). Sesquiterpene lactones from two *Tithonia* species, *Phytochemistry.* **31**, 3139-3141.
- [8] N. C. Baruah, R. P. Sharma, K. P. Madhusudanan, G. Thyagarajan and W. Herz, R. Murari (1979). Sesquiterpene lactones of *Tithonia diversifolia*. Stereochemistry of the tagitinins and related compounds, *J. Org. Chem.* **44**, 1831-1835.
- [9] F. Bohlmann, R. Zeisberg and E. Klein (1975).  $^{13}\text{C-NMR}$ -Spektren von Monoterpenen, *Org. Mag. Res.* **7**, 426-432.
- [10] F. Bohlmann, J. Jakupovic, A. Schuster, R. M. King and H. Robinson (1984). Germacranolide, Hydroxyverbenon und ent-Kaur-15(16)-en-17,19-disäure aus *Helianthus occidentalis* var. *Dowellianus*, *Planta Med.* **50**, 202-203.

**A C G**  
publications

© 2013 Reproduction is free for scientific studies